[go: up one dir, main page]

MX2018000999A - Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico. - Google Patents

Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico.

Info

Publication number
MX2018000999A
MX2018000999A MX2018000999A MX2018000999A MX2018000999A MX 2018000999 A MX2018000999 A MX 2018000999A MX 2018000999 A MX2018000999 A MX 2018000999A MX 2018000999 A MX2018000999 A MX 2018000999A MX 2018000999 A MX2018000999 A MX 2018000999A
Authority
MX
Mexico
Prior art keywords
treatment
immune system
gamma secretase
system dysfunction
secretase modulators
Prior art date
Application number
MX2018000999A
Other languages
English (en)
Inventor
Richard Berenson James
Original Assignee
Oncotracker Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotracker Inc filed Critical Oncotracker Inc
Publication of MX2018000999A publication Critical patent/MX2018000999A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee métodos para el tratamiento de una disfunción del sistema inmune o condiciones asociadas con BCMA soluble usando moduladores o inhibidores gamma secretasa con el fin de restablecer la función inmune y mejorar la eficacia de terapias dirigidas en contra de BCMA presentes en la célula B patogénica.
MX2018000999A 2015-07-24 2016-07-22 Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico. MX2018000999A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562196771P 2015-07-24 2015-07-24
US201562197469P 2015-07-27 2015-07-27
PCT/US2016/043536 WO2017019496A1 (en) 2015-07-24 2016-07-22 Gamma secretase modulators for the treatment of immune system dysfunction

Publications (1)

Publication Number Publication Date
MX2018000999A true MX2018000999A (es) 2018-11-09

Family

ID=57885254

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000999A MX2018000999A (es) 2015-07-24 2016-07-22 Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico.

Country Status (15)

Country Link
US (2) US20180214553A1 (es)
EP (2) EP3324965A4 (es)
JP (2) JP7178902B2 (es)
KR (1) KR20180033232A (es)
CN (2) CN108025001A (es)
AU (1) AU2016297793A1 (es)
BR (1) BR112018001480A2 (es)
CA (1) CA2992557A1 (es)
HK (1) HK1255694A1 (es)
IL (1) IL256903A (es)
MX (1) MX2018000999A (es)
PH (1) PH12018500187A1 (es)
RU (1) RU2748655C2 (es)
SG (1) SG10201913841SA (es)
WO (1) WO2017019496A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2954330A4 (en) 2013-02-08 2016-08-31 Inst Myeloma & Bone Cancer Res IMPROVED DIAGNOSTIC, PROGNOSTIC AND MONITORING PROCEDURES FOR MULTIPLE MYELOMA, CHRONIC LYMPHATIC LEUKEMIA AND NON-HODGKIN B CELL LYMPHOMA
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
US11698369B2 (en) 2016-01-12 2023-07-11 Oncotracker, Inc. Methods for monitoring immune status of a subject
CN109310685B (zh) 2016-04-12 2021-10-29 伊莱利利公司 用于治疗癌症的notch和pi3k/mtor抑制剂的组合疗法
CN109475629A (zh) 2016-05-20 2019-03-15 伊莱利利公司 用notch和pd-1或pd-l1抑制剂的组合治疗
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
ES2949364T3 (es) * 2017-02-17 2023-09-28 Fred Hutchinson Cancer Center Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA
WO2018201051A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
BR112020023975A2 (pt) * 2018-05-24 2021-02-23 Ayala Pharmaceuticals Inc. composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas
IL317554A (en) 2018-06-01 2025-02-01 Novartis Ag Anti-BCMA binding molecules and their uses
CN112203725A (zh) 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途
JP7617033B2 (ja) * 2019-05-22 2025-01-17 ザ クリーブランド クリニック ファウンデーション 背側前腸及び前方ドメイン内胚葉細胞の生成
TW202115114A (zh) 2019-06-24 2021-04-16 瑞士商諾華公司 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法
KR20230009873A (ko) * 2020-03-13 2023-01-17 스프링웍스 테라퓨틱스, 인크. 니로가세스타트 및 bcma-지향 요법과의 병용 요법 및 이의 용도
KR102130281B1 (ko) * 2020-06-19 2020-07-08 성균관대학교산학협력단 감마 세크레타제 억제제를 포함하는 인간거대세포바이러스 감염 질환 예방 또는 치료용 약학적 조성물, 및 감마 세크레타제를 이용한 인간거대세포바이러스 감염 질환 치료제의 스크리닝 방법
WO2022035793A1 (en) 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
IL311128A (en) 2021-09-01 2024-04-01 Springworks Therapeutics Inc Synthesis of neurogestate
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
CN116514678B (zh) * 2022-01-21 2025-04-11 南开大学 新型冠状病毒抑制剂、含有其的药物组合物及其用途
CN114949000B (zh) * 2022-08-02 2022-10-04 卡瑞济(北京)生命科技有限公司 麝香提取物及其增强car-t细胞疗效的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
JP2003520266A (ja) 2000-01-24 2003-07-02 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害薬
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
JP3880051B2 (ja) 2000-11-02 2007-02-14 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害剤としてのスルファミド
DE60234585D1 (es) 2001-02-27 2010-01-14 Us Government
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0326039D0 (en) 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
WO2006001956A2 (en) * 2004-05-20 2006-01-05 The Board Of Trustees Of The University Of Illinois Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
KR20070122497A (ko) * 2005-04-22 2007-12-31 제넨테크, 인크. Ｃｄ20 항체로 치매 또는 알츠하이머병을 치료하는 방법
WO2006123184A2 (en) * 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulphonamido-substituted cyclohexyl sulphones for treatment of cancer
CA2644136A1 (en) * 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
US8633179B2 (en) * 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
US7615883B2 (en) 2007-06-06 2009-11-10 Meheen H Joe Wind driven venturi turbine
AU2008303889A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of neuropeptide SF, alone or in combination with GLP-2, as a therapeutic agent
WO2009035522A1 (en) * 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
JP2011523655A (ja) * 2008-06-03 2011-08-18 フレセニウス メディカル ケア ドイッチュランド ゲーエムベーハー ガンマセクレターゼモジュレータを含む医薬組成物
NZ590127A (en) * 2008-07-08 2012-11-30 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
HUE029619T4 (en) * 2009-03-10 2017-07-28 Biogen Ma Inc Anti-bcma antibodies
US9101559B2 (en) * 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
AU2010265900A1 (en) * 2009-06-26 2012-02-02 University Of Florida Research Foundation, Inc. Protease inhibitors, compositions and methods of use
RU2012136137A (ru) * 2010-01-22 2014-02-27 Дженентек, Инк. Система доставки диагностических и терапевтических средств
JP6385277B2 (ja) * 2011-12-01 2018-09-05 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌治療のための抗ｃｅａｃａｍ１組換え型抗体
CA2889764C (en) * 2012-11-01 2023-10-10 Martin Lipp An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US10316101B2 (en) 2014-04-14 2019-06-11 Cellectis BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy

Also Published As

Publication number Publication date
AU2016297793A1 (en) 2018-02-08
HK1255694A1 (zh) 2019-08-23
CN116808219A (zh) 2023-09-29
CN108025001A (zh) 2018-05-11
BR112018001480A2 (pt) 2018-09-11
US20230405124A1 (en) 2023-12-21
RU2748655C2 (ru) 2021-05-28
JP7178902B2 (ja) 2022-11-28
SG10201913841SA (en) 2020-03-30
WO2017019496A1 (en) 2017-02-02
EP3662909A1 (en) 2020-06-10
IL256903A (en) 2018-03-29
CA2992557A1 (en) 2017-02-02
JP2021167339A (ja) 2021-10-21
EP3324965A1 (en) 2018-05-30
US20180214553A1 (en) 2018-08-02
RU2018105980A3 (es) 2019-12-26
RU2018105980A (ru) 2019-08-16
EP3324965A4 (en) 2019-07-03
PH12018500187A1 (en) 2018-07-30
JP2018521081A (ja) 2018-08-02
KR20180033232A (ko) 2018-04-02

Similar Documents

Publication Publication Date Title
MX2018000999A (es) Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico.
MX2021004479A (es) Agentes biologicos y su uso en plantas.
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
CL2018000853A1 (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer.
BR112017006664A2 (pt) terapias de combinação
ECSP17073743A (es) Moduladores de k-ras
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2017003307A1 (es) Sistema de administración dirigida de principio activo celular
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
SI3285803T1 (sl) Postopki za zdravljenje in preprečevanje migrenskega glavobola
MY187540A (en) Compounds active towards bromodomains
JO3553B1 (ar) تعديل المناعة ضد الورم
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
PL3485890T3 (pl) Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
PH12019501373A1 (en) Methods of treating cochlears synaptopathy
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
PH12017500602A1 (en) Methods for treating ocular conditions
EA201892672A1 (ru) Лечение боли
PH12016501838A1 (en) Compounds and their methods of use
AR103119A1 (es) Uso de elsiglutida para tratar mucositis gastrointestinal, incluyendo diarrea inducida por quimioterapia
MX385322B (es) Uso de sedoheptulosa para la prevención y tratamiento de inflamación.